Literature DB >> 31133370

A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer.

Ethan M Steele1, Jordan A Holmes2.   

Abstract

Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependent on pretreatment risk group and unfortunately, a proportion of patients fail primary treatment. The treatment of recurrence after primary radiation is rapidly changing with advances in imaging and it is important to distinguish those with a local failure from those with distant failure. If disease remains locally confined, salvage treatment with a variety of techniques can still provide a potential cure. Patients with distant failure are often treated with androgen deprivation, or in those with a shorter life expectancy, conservative management. In patients with a higher burden of metastatic disease, there is emerging evidence that chemotherapy and advanced androgen therapy can improve survival. We review the relevant literature on available salvage treatment options and appropriate patient selection for patients with recurrent prostate cancer after RT. We report on the efficacy and adverse effects of the currently available local salvage modalities including salvage radical prostatectomy, high dose rate and low dose rate brachytherapy, cryotherapy, high intensity focused ultrasound, and stereotactic body RT. We additionally discuss diagnosis of oligometastatic disease on imaging and current approaches to treatment with either radiation or surgery. While a full review of chemotherapy and advanced androgen therapies is beyond the scope of this article we briefly discuss their use in the treatment of newly diagnosed recurrence after radiation.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Prostate Cancer; Radiation Recurrence; Radiation Therapy; Salvage Treatment Modalities; Surgery

Year:  2019        PMID: 31133370     DOI: 10.1016/j.urolonc.2019.04.030

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.

Authors:  Finbar Slevin; Samantha Hodgson; Sree Lakshmi Rodda; Peter Bownes; David Bottomley; Ese Adiotomre; Bashar Al-Qaisieh; Emma Dugdale; Oliver Hulson; Joshua Mason; Jonathan Smith; Ann M Henry
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-27

2.  Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.

Authors:  Thomas Willigenburg; Ellis Beld; Jochem Hes; Jan J W Lagendijk; Hans C J de Boer; Marinus A Moerland; Jochem R N van der Voort van Zyp
Journal:  Phys Imaging Radiat Oncol       Date:  2020-08-07

3.  Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients.

Authors:  Frederik R Teunissen; Ruud C Wortel; Jochem Hes; Thomas Willigenburg; Eline N de Groot-van Breugel; Johannes C J de Boer; Harm H E van Melick; Helena M Verkooijen; Jochem R N van der Voort van Zyp
Journal:  Phys Imaging Radiat Oncol       Date:  2021-09-21

4.  Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.

Authors:  Ron Lewin; Uri Amit; Menachem Laufer; Raanan Berger; Zohar Dotan; Liran Domachevsky; Tima Davidson; Orith Portnoy; Lev Tsvang; Maoz Ben-Ayun; Ilana Weiss; Zvi Symon
Journal:  Radiat Oncol       Date:  2021-06-23       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.